Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Arcus Biosciences in a research report issued on Tuesday, February 18th. HC Wainwright analyst E. Bodnar expects that the company will post earnings per share of ($1.30) for the quarter. HC Wainwright has a “Neutral” rating and a $18.00 price objective on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.20) per share. HC Wainwright also issued estimates for Arcus Biosciences’ Q2 2025 earnings at ($1.10) EPS, Q3 2025 earnings at ($1.15) EPS, Q4 2025 earnings at ($1.15) EPS and FY2029 earnings at ($1.80) EPS.
Several other research firms have also recently weighed in on RCUS. Wedbush reissued an “outperform” rating and issued a $36.00 price objective on shares of Arcus Biosciences in a research report on Thursday, November 7th. Barclays boosted their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a report on Friday, October 25th. Bank of America reduced their price target on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Wednesday. Finally, Morgan Stanley lowered their price objective on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating on the stock in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $29.50.
Arcus Biosciences Price Performance
Shares of NYSE RCUS opened at $10.76 on Thursday. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $984.21 million, a PE ratio of -3.41 and a beta of 0.84. The stock’s 50 day moving average price is $14.02 and its 200-day moving average price is $15.56. Arcus Biosciences has a twelve month low of $10.63 and a twelve month high of $20.31.
Institutional Investors Weigh In On Arcus Biosciences
Several institutional investors have recently made changes to their positions in RCUS. GSA Capital Partners LLP raised its stake in shares of Arcus Biosciences by 17.8% during the 3rd quarter. GSA Capital Partners LLP now owns 187,415 shares of the company’s stock valued at $2,866,000 after purchasing an additional 28,307 shares during the period. Quest Partners LLC increased its position in shares of Arcus Biosciences by 40,904.3% during the third quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after buying an additional 9,408 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in shares of Arcus Biosciences by 25.1% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 931,048 shares of the company’s stock worth $14,236,000 after buying an additional 186,750 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Arcus Biosciences in the third quarter valued at approximately $244,000. Finally, Massachusetts Financial Services Co. MA grew its stake in Arcus Biosciences by 39.0% during the third quarter. Massachusetts Financial Services Co. MA now owns 80,889 shares of the company’s stock valued at $1,237,000 after acquiring an additional 22,716 shares in the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.
Insider Activity at Arcus Biosciences
In related news, CFO Robert C. Goeltz II sold 3,594 shares of Arcus Biosciences stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total value of $53,910.00. Following the completion of the transaction, the chief financial officer now directly owns 60,138 shares in the company, valued at approximately $902,070. The trade was a 5.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 12.30% of the stock is currently owned by company insiders.
About Arcus Biosciences
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
Featured Articles
- Five stocks we like better than Arcus Biosciences
- How to Profit From Value Investing
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- Most Volatile Stocks, What Investors Need to Know
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- What Does a Stock Split Mean?
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.